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In this study of 102 patients with culture-positive chronic treatment failure or repeatedly relapsed 
pulmonary tuberculosis receiving chemotherapy, 56 received an injection of killed Mycobacterium vaccae 
as immunotherapy after 1 month of treatment. At the start of treatment, there was little difference 
between those receiving immunotherapy and the 46 patients in the control group receiving chemotherapy 
alone. Thereafter, the two groups diverged so that 1 yr later, 43 of 56 (77%) patients receiving M. vaccae 
had a successful outcome, in comparison with 24 of 46 (52%) patients receiving chemotherapy alone 
(PcO.02). 
Successful results were obtained from patients infected with drug-resistant bacilli, 20 of 32 (63%) 
patients compared with 11 of 25 (44%) patients, respectively, as well as from fully drug-sensitive cases (23 
of 24 compared with 12 of 21 patients; P=O*OO4). At the final follow-up after 22 months, 13 of 56 
patients receiving immunotherapy had an unfavourable outcome compared with 26 of 46 members of the 
control group (P=O*OOO6). During the study, 16 patients died of tuberculosis (six after immunotherapy), 
and 12 were lost to follow-up. 
Not only was bacteriological success improved by immunotherapy, chest X-rays showed markedly 
better resolution of cavities and other radiological lesions, recovery of body weight was improved, and 
the mean erythrocyte sedimentation rate returned almost to normal (P<O-001) in comparison with those 
receiving chemotherapy alone. These changes were seen even in those failing bacteriological cure, 
suggesting that the immunotherapy had been effective, but that bacilli were replicating in an extracellular 
situation, protecting them from its effects. 
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Introduction treatment, or relapse to become chronic cases. 
Major problems resulting in patients developing 
chronic relapsed tuberculosis include poor treat- 
ment and the development of drug resistance 
by the bacilli. Some patients are first infected 
with drug-resistant bacilli, known as primary 
drug resistance, and they start with a consider- 
able disadvantage and are more likely to fail 
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Others, first infected with drug-susceptible 
bacilli, receive poor or inadequate treatment for 
a variety of reasons, and their infecting bacilli 
acquire secondary resistance, making them more 
difficult to treat. Still others remain infected 
with fully drug-susceptible bacilli, but either 
receive such poor treatment, or comply so 
poorly with properly prescribed treatment, that 
their disease is not cured and they too develop 
chronic relapsing disease. 
Approximately 20 000 new cases of pulmon- 
ary tuberculosis are diagnosed in Romania each 
year, and there is a continuous backlog of about 
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TABLE 1. Initial data on patients with sputum cultures positive for Mycobacterium 
tuberculosis entering the two arms of the study 
Mycobacterium vaccae 
recipients 
Placebo 
recipients 
Numbers 
Sex 
Mean age (years) 
Bacteriology 
AFB visible in sputum 
Cultures showing resistance to 
one or more drugs 
Multi-drug resistance? 
Clinical 
Mean weight (kg) 
Mean ESR 
Radiology 
No. with cavities 
Mean cavity surface area 
Mean lesional score 
56 
9F 47M 
44.1 f 12.9 
53156 (95%) 
32/51*(63%) 
18/51*(35%) 
58-4 f 10.1 
56.8 f 33.8 
50/56 (89%) 
83.7 f 99.7 
2.4 f 0.6 
46 
14F 32M 
40.3 * 11.3 
45/46 (98%) 
25/44*(57%) 
14/44*(32%) 
P= 0*04$ 53.9 f 9.7 
65.2 f 27.5 
41/45*(89%) 
63.7 f 56.1 
2.5 f O-5 
ESR, erythrocyte sedimentation rate; AFB, acid-fast bacilli. *Data not available for the 
missing numbers; tCultures resistant to rifampcin and isoniazid, with or without other 
drugs;-$Student’s t-test. 
1000 chronic patients, many with drug resist- 
ance, requiring further treatment at any time. 
Such patients are notoriously difficult to cure, 
even if they can be made to comply with their 
chemotherapy. Against this background, the 
present study was designed to investigate 
the contribution towards successful treatment 
that might be made by an immunotherapeutic 
injection of killed Mycobacterium vaccae (1). 
For the present study, 102 patients with 
chronic treatment failure or multiply-relapsed 
pulmonary tuberculosis were recruited to receive 
a course of the chemotherapy standard for 
Romania, with or without the addition of an 
injection of killed M. vaccae 1 month after 
starting treatment. Although it was intended 
that the study should be randomized, compas- 
sion broke through design and a higher pro- 
portion with more severe disease received the 
immunotherapy. 
Materials and Methods 
sis attending hospitals in Bucharest and Brasov 
in Romania for treatment of their chronic treat- 
ment failure or multiply-relapsed disease. They 
were selected for being sputum culture positive 
for Mycobacterium tuberculosis, and for having a 
history of previous unsuccessful treatment, the 
majority having started many such courses. 
Although the authors cannot be sure that none 
of the patients had completed previous courses, 
most were regular defaulters, failing to comply 
with treatment after the first few weeks of each 
course had produced some clinical improvement. 
In the present study, these patients were started 
on a new course of treatment, encouraged to 
comply, and followed-up in their homes when 
necessary. The initial data obtained from the 
patients at the start of their course of chemo- 
therapy is shown in Table 1. With the degree and 
severity of tuberculous disease present in such a 
group of patients, no exclusion criteria were 
applied, except that those who did not agree to 
participate were omitted. 
THE PATIENTS TREATMENT 
The study population consisted of 102 adult 
patients (2 18 years) with pulmonary tuberculo- 
Treatment consisted of the standard course used 
in Romania of 2 months of rifampicin, isoniazid, 
CHRONIC OR RELAPSED TB IN ROMANIA 23 
streptomycin and pyrazinamide taken twice 
weekly, followed by 4 months of rifampicin 
and isoniazid twice weekly (2HRZS,/4HR,). 
The dosage was: isoniazid and rifampicin, 
15mgkg-’ body weight to a maximum of 
900 mg; pyrazinamide, 60 mg kg - ’ to a maxi- 
mum of 4.5 g; streptomycin, 1 g. As far as poss- 
ible, patients were hospitalized for the first 2 
months of treatment. Chemotherapy was not 
strictly supervised but compliance was encour- 
aged. Ideally, patients found to have resistance 
to a drug would have that drug substituted for 
another in their course of treatment, but at the 
time of the present study, second-line drugs were 
not generally available in Romania. 
The immunotherapy was the same as that 
described previously (l-4) consisting of an 
intradermal injection of 0.1 ml M. vaccae strain 
NCTC 11659, Batch A5, given over a deltoid 
muscle. The reagent contained 10 mg ml - ’ wet 
weight of whole, killed (autoclaved) bacilli in 
borate-buffered saline. Patients allocated to the 
control group received a similar injection, but of 
saline. Injections were given after 1 month of 
chemotherapy had been completed. Patients 
were not told which injection they received, but 
this was known to the physicians who gave the 
injections. Rather fewer women (nine of 56) 
received immunotherapy than received placebo 
(14 of 46), probably because the most severely ill 
patients tended to be directed towards immuno- 
therapy. This sex imbalance was responsible for 
the lower average body weight in the placebo 
group. The same randomization schedule was 
used for this study and that of newly-diagnosed 
patients (2), thus numbers are not quite evenly 
balanced in the two studies. 
CLINICAL STUDIES 
Patients were weighed on the first day of their 
current course of treatment, and were clinically 
examined. This was repeated at occasional inter- 
vals, after 2 months of treatment, at the end of 
chemotherapy and 6 months after its completion. 
RADIOLOGICAL INVESTIGATION 
Chest X-rays were performed at the start of the 
study, and were repeated at the end of treatment 
and 6 months later. The results were reported as 
approximate areas of inner cavity wall, calcu- 
lated by measuring cavity diameters on radio- 
graphs and applying the formula: Pi times the 
square of each diameter, and as a score of the 
extent of lesions from 0 to 3. This was based on 
methods developed by Simon (5) modified by 
the American Thoracic Society, and further 
modified locally. Radiographs were read by 
experienced hospital staff who did not know that 
the patients were in a special study, or which 
intervention they had received. 
LABORATORY INVESTIGATIONS 
Sputum samples were taken for culture and 
microscopy for mycobacteria at the start of the 
study, and were repeated at intervals. Results 
of those obtained after 2 months of treatment, at 
the end of chemotherapy and 6 months later are 
reported. Drug-susceptibility studies were 
performed on initial cultures, and results are 
available for 95 of 102 patients. Venous blood 
samples were taken at the start, after 2 months of 
treatment, at the end of treatment and 6 months 
later for erythrocyte sedimentation rate (ESR, by 
the Westergren method). These investigations 
were also carried out by staff who did not know 
which intervention patients had received. 
STATISTICS 
The two-tailed Fisher’s exact test, Student’s 
t-test, and the two-tailed, unpaired Mann- 
Whitney test were used to evaluate the results. 
Results 
The majority of results are shown in a series of 
tables based on information obtained 2 months 
after starting chemotherapy and 1 month after 
intervention (Table 2), at the end of 6 months 
chemotherapy (Table 3), and after 1 yr (Table 4). 
More detailed analyses of progression of cavities 
seen on chest X-rays are shown in Table 5. 
At the time of admission to the study, every 
patient had tubercle bacilli demonstrable in spu- 
tum by culture, and in most cases by microscopy 
(98 of 102 patients). Drug-sensitivity tests to 
streptomycin (S), isoniazid (H), rifampicin (R), 
ethambutol (E) and pyrazinamide (Z) were per- 
formed on cultures from 95 of the patients. These 
showed 21 patients to be infected with bacilli 
resistant to at least one drug (11 M. vaccae 
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TABLE 2. Results obtained 2 months after starting chemotherapy, and 1 month after 
intervention 
Mycobacterium vaccae Placebo 
recipients recipients 
Bacteriology 
Microscopy positive 
Culture positive 
Culture + ve DR 
Culture +ve MDR 
Clinical 
Body weight 
ESR 
16/53*(30%) P<O*O2$ 25/45*(56%) 
25156 (45%) P=O-0083 32/45*(72%) 
16/32 (50%) P=O*O5$ 19/25 (76%) 
lo/18 (56%) 1 l/14 (79%) 
59.7 f 9.1 (1.3 kg)? 55.8 f 10.5 (1.9 kg)? 
34.9 f 30.3 PCO*O2§ 44.4 f 24.6 
DR, drug resistance; MDR, multi-drug resistance; ESR, erythrocyte sedimentation rate. 
*Data not available for the missing numbers; TIncreases in body weight; ITwo-tailed 
Fisher’s exact test; @Student’s t-test. 
TABLE 3. Results obtained at the end of chemotherapy and 5 months after intervention 
Mycobacterium vaccae Placebo 
recipients recipients 
Total patients 
Lost to follow-up 
Assessed 
Deaths 
Treatment success 
Require re-treatment 
Bacteriology 
Microscopy positive 
Culture positive 
Culture + ve DR 
Culture + ve MDR 
Clinical 
Body weight 
ESR 
Radiology 
Still with cavities 
Cavity surface area 
With reduced cavities 
With larger cavities 
Mean lesional score 
56 
1 
55 
4 
40155 (73%) 
10 
7/47*(11%) 
10/50*(20%) 
8/26*(31%) 
5/14*(36%) 
62.3 f 9.5 (3.9 kg)? 
26.0 f 20.5 
32/47*(68%) 
47.2 f 56.8 cm2 
45/47 (96%) 
2/47 (4%) 
1.7 f 0.7 
46 
1 
45 
2 
31/45 (69%) 
12 
P= 0.02s 14/43 (30%) 
12/43 (28%) 
8/23 (35%) 
4112 (33%) 
57.6 f 8.7 (3.7 kg)? 
PCO.0211 38-O f 24.3 
36143 (84%)$ 
50.6 f 46.8 cm2 
P<O*O2$ 33/43 (77%) 
P<O.O5§ 8/43 (19%)$ 
P<O-0111 2.1 Gz 0.7 
DR, drug resistance; MDR, multi-drug resistance; ESR, erythrocyte sedimentation rate. 
IIncluding two additional patients developing cavities; *Data not available for the missing 
numbers; TIncreases in body weight; @Two-tailed Fisher’s exact test; &Student’s t-test. 
recipients), 26 were resistant to two drugs (14 multi-drug resistant bacilli, defined as resistant to 
A4. vaccae recipients), and 10 were resistant both R and H at least (18 M. vaccae recipients). 
to three or four drugs (seven M. vaccae recipi- Resulting from a preponderance of females in 
ents). Thirty-two patients were infected with the placebo group (14 of 46, compared with nine 
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TABLE 4. Results obtained 6 months after the end of chemotherapy 
Mycobacterium vaccae Placebo 
recipients recipients 
Total patients 
Lost to follow-up 
Died during treatment 
Given re-treatment 
Re-treatment success 
Assessed 
Further deaths 
Remain cured 
Bacteriology 
Microscopy positive 
Culture positive 
Culture +ve DR 
Culture +ve MDR 
Clinica@ 
Body weight 
ESR 
Radiologyf 
Still with cavities 
Cavity surface area 
Cavities reduced 
Cavities increased 
Mean lesional score 
56 
2 
4 
10 
5110 
40 
0 
38/39*(97%) 
l/39*(3%) 
l/39*(3%) 
o/17 
O/8 
64.5 f 9.6 (6.1 kg)? 
19.9 +z 15.3 
17/45 (38%) 
32.7 f 31.2 
40145 (89%) 
l/45 (2%) 
1.4 f 0.6 
P<O.OOlII 
P<O*Ol§ 
P<O.Ol§ 
P<O*OO11~ 
46 
2 
4 
12 
3112 
30 
2 
21/30 (70%) 
7128 (25%) 
7/28 (25%) 
4/13 (31%) 
2/6 (33%) 
58.5 f 9.2 (4.6 kg)? 
41.2 f 22.7 
22132 (69%) 
45.4 xt 39.4 
23/32 (72%) 
7132 (23%) 
2.0 f 0.7 
DR, drug resistance; MDR, multi-drug resistance; ESR, erythrocyte sedimentation rate. 
*Data not available for the missing numbers; TIncreases in body weight; $Based on all 
patients followed up at 1 yr; §Two-tailed Fisher’s exact test; listudent’s t-test. 
of 56), the mean body weight of this group was 
somewhat lower than that of immunotherapy 
recipients. The same proportion of patients in 
each treatment group had radiologically detect- 
able cavities, although those of immunotherapy 
recipients tended to be larger. 
RESULTS AT 2 MONTHS 
A month after its injection, significantly fewer 
patients receiving M vaccae had positive cul- 
tures for tubercle bacilli (P=O-008) or acid-fast 
bacilli visible in their sputum. Only 16 of 32 
patients infected with bacilli showing resistance 
to R and H were still culture positive in the 
immunotherapy group, compared with 19 of 25 
in the placebo group (P<O*O5). Body weight 
increased by over 1 kg in both groups, but ESR 
was significantly lower amongst immunotherapy 
recipients (PCO.02). 
RESULTS AFTER 6 MONTHS 
By the end of chemotherapy, the differences in 
bacteriological results between the two groups 
showed a trend in favour of immunotherapy 
recipients, but only sputum microscopy 
remained statistically significant (P<O*02, see 
Table 3). Regain of body weight was more 
than 3 kg in both treatment groups. Erythrocyte 
sedimentation rates of the M. vaccae recipients 
were significantly lower than those of the control 
group (WO.02). Radiological differences 
between the two groups were apparent with 45 
of 47 immunotherapy recipients showing a sig- 
nificant reduction (PcO.05) in cavity surface 
area, and only two of 47 showing an increase. In 
comparison, a smaller proportion, 33 of 43 
(P<O-02), of placebo recipients showed a non- 
significant reduction in cavity surface area, and 
eight of 43 showed an increase in cavitation 
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TABLE 5. Changes in cavitation seen in patients with a full set of three X-rays, one taken 
at the start of treatment, another at the end of treatment and the third 6months after this 
Numbers At start 
Area of cavity walls 
After 6 months After 1 year 
Patients showing progressive resolution of cavities 
M. vaccae 36/42 (86%) 72.3 f 77.7 
PCO.O2$ 
Placebo 18/31 (58%) 71.6 f 68.0 
Patients showing moderate resolution of cavities 
M. vaccae 4142 (9.5%) 91.0 f 69.9 
Placebo 5/31 (16%) 40.0 It 14-l 
Patients with worsening cavities 
M vaccae l/42 (2.4%) 48 
P<O.O2$ 
Placebo 7/31 (23%) 28.9 f 27-7 
34.6 f 55.9 8.3 f 19*1* 
39.4 f 42.3 16.0 f 24.6t 
60.0 f 33.6 42-5 f 43.5 
26.0 f 16.7 27-2 f 12.0 
68 68 
64.3 A 32.0 83.9 f 41.1 
The figures shown are for calculated internal surface areas of cavities. M. vaccae, 
Mycobacterium vaccae. Cavities completely resolved: *23/36 (64%) and -t 808 (44%). 
fTwo-tailed Fisher’s exact test. Note that results are not shown in this table for the six 
patients in the immunotherapy group and two patients in the placebo group who did not 
show cavitation. 
(P<O*O5), including two patients who developed 
cavities during treatment. Fifteen patients in the 
immunotherapy group starting with cavities no 
longer had them, compared with seven patients 
in the control group. The radiological lesional 
score index was also significantly lower in the 
group receiving M. vaccae (BO.01) in compari- 
son with the group receiving placebo. 
Ten patients from the immunotherapy group 
and 12 from the placebo group required courses 
of re-treatment, coming out from further analysis. 
RESULTS AFTER I YR 
Six months after the end of chemotherapy (see 
Table 4), 39 patients from the immunotherapy 
group and 30 from the placebo group, appar- 
ently cured at the end of chemotherapy, were 
available for re-assessment. Amongst irnmuno- 
therapy recipients, one patient had relapsed to 
smear and culture positivity, compared with 
seven relapses in the placebo group (P=O*O2), 
and two deaths. The relapsed patients were 
prescribed courses of re-treatment. 
For all patients followed-up at 1 year, ESRs 
were significantly lower among h4. vaccae recipi- 
ents (P<O*OOl), and body weights had increased 
by 6.1 kg in the M. vaccae group compared with 
4.6 kg in the placebo group. Radiological par- 
ameters showed much greater improvement in 
the immunotherapy group, with significantly 
fewer patients still with detectable cavities 
@<O-01), and only one patient showed increased 
cavitation in comparison with seven patients in 
the placebo group (P<O*Ol). The mean X-ray 
lesional score of the immunotherapy group was 
significantly further reduced since the end of 
chemotherapy (P<O*O3), whereas the small 
improvement in this parameter was far from 
significant (DO-5) amongst placebo recipients. 
RESULTS FOR THOSE INFECTED WITH 
DRUG-RESISTANT BACILLI 
In the immunotherapy group, 20 of 32 (63%) 
patients infected with bacilli resistant to one or 
more drugs were bacteriologically cured, three of 
them after re-treatment, and all four who died 
were infected with bacilli resistant to R and at 
least one other drug, in two cases H. In the 
placebo group, 11 of 25 (44%) patients infected 
with bacilli resistant to one or more drugs were 
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cured, two of them after re-treatment, and three 
of the four deaths were of patients infected with 
bacilli resistant to both R and H. 
REGAIN OF BODY WEIGHT 
Besides the mean body weights shown in the 
tables, in those patients for whom a complete set 
of four data points is available, whatever their 
bacteriological outcome (47 in the M. vaccae 
group and 33 in the control group), there are 
differences in progression of weight regain. In 
the immunotherapy group, 42 of 47 (89%) 
patients improved in weight, compared with 22 
of 33 (67%) members of the placebo group 
(BO.02). Of these, 13 of 47 (28%) showed a 
steady increase at each time point in the immu- 
notherapy group, compared with three of 33 
(9%) from the placebo group (P<O*O2). Only two 
of 47 (4%) A4. vaccae recipients showed an 
overall fall in weight between the first and last 
time points, in comparison with 10 of 33 (30%) 
placebo recipients (P<O*OO5). 
RADIOLOGICAL PROGRESSION 
Data illustrating this, and based on patients for 
whom a complete set of three radiographs is 
available (48 in the M. vaccae group, 33 in the 
placebo group), are shown in Table 5 for the 
progression of cavities in the two intervention 
‘groups. The six patients in the immunotherapy 
group and two in the placebo group who never 
showed cavitation are left out of the table and 
calculations. 
At the start of the study, there was no differ- 
ence in the extent of cavitation between the two 
groups (Mann-Whitney U=563, P=O*33), and 
neither was there at the end of chemotherapy 
(U=545, P=O*24). At 12 months, however, the 
extent of cavitation in the A4. vaccae recipient 
group was significantly less than in the placebo 
group (U= 398, P=O*OOS). 
Of those receiving immunotherapy, 36 of 42 
(86%) showed progressively less cavitation 
with time, in comparison with 18 of 31 (58%) 
members of the placebo group (PcO.02). Only one 
M. vaccue recipient showed worsening cavitation 
compared with seven of 31 placebo recipients 
(P<O*O2), two of whom developed cavities after 
starting treatment. Cavitation was not detectable 
on the 12-month radiographs in 24 of 42 (57%) 
members of the immunotherapy group, and eight 
of 31 (26%) placebo recipients (P~O.001). 
RESULTS AT LATEST FOLLOW-UP 
Data was available after a mean of 22 months on 
43 immunotherapy recipients and 34 placebo 
recipients who had been fully followed-up to 
1 yr. These included 28 and 18, respectively, of 
those cured at 6 and 12 months. Three of 28 
members of M. vuccae group and five of 18 
members of the placebo group had relapsed to 
sputum culture positivity. Eleven M. vaccue 
recipients, four sputum positive for AFB, and 
eight placebo recipients, seven sputum positive 
for AFB, died between the 1 yr and final 
follow-ups (P= 0.06). 
In general, out of all patients entering the study, 
13 of 56 M. vuccue recipients and 26 of 46 placebo 
recipients had unfavourable outcomes due to 
tuberculosis (P=O.O006) at the last analysis. 
Discussion 
The results obtained support the contention that 
immunotherapy with A4. vuccae makes a con- 
siderable contribution towards the treatment of 
tuberculosis (3,4), particularly in patients in 
whom chemotherapy alone has been repeatedly 
unsuccessful, and in those infected with drug- 
resistant bacilli (6). Even so, it is likely that 
patients receiving chemotherapy alone have done 
better in the present study than they would have 
in standard practice. Since the patients enrolled 
knew they were in a special study, they may well 
have complied better, and their attendants may 
have been more encouraging, than under routine 
conditions. Despite this, it is not possible to 
know the degree to which defaulting occurred 
without directly observed therapy. The evidence 
from Nigeria (4) suggests that immunotherapy 
recipients tend to stop chemotherapy earlier be- 
cause their disease resolves at a faster rate and 
they feel better sooner. The authors cannot be 
sure that this was the case in Romania, but 
suspect that those for whom data is missing when 
they failed to keep appointments might also have 
complied least well with their treatment. 
In the authors’ study of newly-diagnosed 
pulmonary tuberculosis in Romania (2) 182 of 
193 (94%) patients remained culture negative 
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6 months after the end of treatment; 88 of 91 
(97%) receiving immunotherapy plus chemo- 
therapy, and 94 of 102 (92%) receiving chemo- 
therapy alone. In comparison, in the current 
study, if those successfully re-treated are 
included, 67 of 102 (66O/) patients were culture 
negative at 1 yr; 43 of 56 (77%) receiving immu- 
notherapy, and 24 of 46 (52%) receiving placebo 
(PCO-02). 
Patients entering the two arms of the study 
were very similar in their characteristics (Table 
l), but by 1 month after intervention, those 
receiving immunotherapy showed clear advan- 
tages bacteriologically and in reduction in ESR 
(Table 2). It is not surprising that the bacterio- 
logical advantage was no longer apparent by the 
end of chemotherapy, although regain in body 
weight was significantly improved, and there was 
continued reduction in ESR (Table 3). Striking 
from this table was the better radiological 
improvement seen after immunotherapy. Six 
months after completion of chemotherapy, the 
advantages of immunotherapy are again appar- 
ent, partly due to a 15% relapse rate in the 
placebo group, compared with only a 3% relapse 
after M vaccae (PCO.05). 
As well as putting on more weight, a greater 
number of immunotherapy recipients than pla- 
cebo recipients showed progressive regain of 
body weight (P<O*O2), and fewer showed weight 
loss (P<O*OO5). Table 5, showing radiological 
changes taking place during and after chemo- 
therapy, also shows distinct advantages for those 
receiving immunotherapy. Thirty-six of 42 (86%) 
and 18 of 31 (58%) patients showed progressive 
resolution of cavities in the immunotherapy and 
placebo groups, respectively (P~0.02). Cavities 
had completely closed by 12 months in 24 of 42 
(57%) M. vaccae recipients and eight of 31 (26%) 
placebo recipients (P<O*Ol). This improved 
radiological appearance associated with immuno- 
therapy was noted in an early study of 
M. vuccue in Kuwait (7), in a pilot study in 
Argentina (8), and in the study in Nigeria (4) 
where improved closure of cavities was particu- 
larly mentioned. Both the increased rate of regain 
of body weight and the improved resolution 
of chest X-rays are likely to be the result 
of changes in circulating cytokines. Notable 
amongst these may be a reduced influence of Th2 
cytokines on the toxicity of circulating tumour 
necrosis factor, and a reduction in fibrosis, per- 
haps associated with increased levels of IL12 (9). 
The present study may contribute to knowl- 
edge of who does not respond to immuno- 
therapy, and how this immunotherapy may 
work, in that regain of body weight, reduction in 
ESR and reduction in the size of cavities may 
occur without a successful bacteriological out- 
come being achieved. Even in treatment failures, 
better progression is seen in the immunotherapy 
recipients in comparison with those receiving 
chemotherapy alone. A likely explanation for 
bacteriological failure in patients showing suc- 
cessful responses in other parameters is that their 
bacilli are multiplying outside of cells on the 
denuded walls of cavities and damaged airways. 
Immunotherapy with M vuccue induces cell- 
mediated antibacterial mechanisms which could 
not be expected to eliminate extracellular bacilli, 
but they would be expected to limit the damage 
mediated by circulating tumour necrosis factor. 
In the study of newly-diagnosed patients in 
Romania (2) the authors found 25 of 175 (14%) 
patients to be initially infected with bacilli show- 
ing some drug resistance, many of them prob- 
ably true cases of primary drug resistance. 
Among them were seven of 175 patients infected 
with bacilli resistant to R and H, complying with 
the modern definition of multi-drug resistance. 
In the present study of patients with chronig 
tuberculosis, 57 of 95 (60%) patients showed 
resistance to at least one drug, and 32 (34%) of 
them were multi-drug resistant, the majority of 
them likely to be of secondary, or acquired, type. 
This illustrates the strong association of drug 
resistance, even to single drugs, with the 
development of chronic disease. 
There is no reason to think that bacilli with 
resistance to anti-tuberculosis drugs should be 
able to resist the immune system. However, 
difficulty in lowering the tissue load of such 
bacilli would leave many more alive and multi- 
plying than would be the case with fully drug- 
susceptible bacilli, of which the majority would 
be killed by early bactericidal action (10) before 
the M vuccue is administered. Thus, at the end 
of a year amongst immunotherapy recipients 
and including those re-treated, 20 of 32 (63%) 
patients infected with bacilli resistant to at least 
one drug were cured, compared with 23 of 24 
(96%) patients infected with fully drug-sensitive 
bacilli. Of placebo recipients, 11 of 25 (44%) 
patients infected with bacilli showing some drug 
resistance were cured, including two after 
re-treatment, compared with 12 of 21 (57%) 
patients infected with drug-sensitive bacilli. 
Results previously published from Iran (6) 
showed patients with a history of disease of less 
than 2 yr, and with bacilli showing initial multi- 
drug resistance, to be curable with a combi- 
nation of drugs to which they showed resistance 
plus a single injection of killed M. vaccae. 
Patients with longer histories in that study 
required repeated injections of A4. vaccae, at 
intervals of between 2 and 6 months, before a 
proportion of them were cured. All of the 
present patients had histories of disease longer 
than 2 yr, yet the cure rate was significantly 
improved by a single injection. This was particu- 
larly obvious in those infected with drug- 
sensitive bacilli (23 of 24 compared with 12 of 
21; P<O*OO4), and showed a trend amongst those 
showing drug resistance (20 of 32 compared with 
11 of 25; P=O*13). 
Of all the patients entering the present study, 
14 receiving M vaccae and 24 receiving chemo- 
therapy alone required at least one course of 
re-treatment because of treatment failure or 
relapse (WO.01). This re-treatment was success- 
ful in five of 14 and two of 24 patients, respect- 
ively, suggesting that the beneficial effects of 
immunotherapy extend to subsequent courses of 
re-treatment, as well as to the course of treat- 
ment during which it was administered. Very 
similar results were obtained in the authors’ 
study of newly-diagnosed tuberculosis patients 
(2). 
There was no significant difference in numbers 
of patients dying from tuberculosis, whether 
they received M. vaccae or not, but it remains 
possible that administering M. vaccae earlier in 
treatment or giving second or further injections 
might have reduced mortality. The improve- 
ments seen in weight regain, ESR and reduced 
cavitation, even in those who were not cured 
after immunotherapy, does suggest that a further 
injection, given perhaps 2 or 3 months after the 
first, might have improved the outcome (6). Pilot 
studies are already in progress to investigate this 
and to find out whether immunotherapy would 
be more effective if given earlier in the course of 
chemotherapy. All of the parameters investi- 
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gated were found to be useful measures of the 
efficacy of immunotherapy. 
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